- $250.74m
- $172.29m
- $338.75m
- 68
- 54
- 47
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.15 | ||
| Price to Tang. Book | 1.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.2% | ||
| Return on Equity | -62.42% | ||
| Operating Margin | -61.36% | ||
Financial Summary
| Year End 31st May | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 270.63 | 264.16 | 291.01 | 316.22 | 338.75 | 287.31 | 287.25 | 5.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Directors
- Howard Donnelly NEC (60)
- James Clemmer PRE (57)
- Stephen Trowbridge CFO (47)
- Richard Rosenzweig SVP (54)
- Chad Campbell SVP (50)
- Scott Centea SVP (43)
- Laura Piccinini SVP (51)
- Marna Bronfenmoore SVP (54)
- Benjamin Davis SVP (56)
- David Helsel SVP (57)
- Warren Nighan SVP (52)
- Juan Serna OTH
- Eileen Auen IND (58)
- Wesley Johnson IND (63)
- Karen Licitra IND (62)
- Dennis Meteny IND (68)
- Jan Reed IND (61)
- Michael Tarnoff IND (53)
- Last Annual
- May 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- July 30th, 1992
- Public Since
- May 27th, 2004
- No. of Shareholders
- 169
- No. of Employees
- 815
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 40,054,533
- Address
- 14 Plaza Dr, LATHAM, 12110-2166
- Web
- https://www.angiodynamics.com/
- Phone
- +1 5187981215
- Auditors
- Deloitte & Touche LLP
Latest News for ANGO
Upcoming Events for ANGO
Q4 2024 AngioDynamics Inc Earnings Release
Q1 2025 AngioDynamics Inc Earnings Release
Similar to ANGO
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 19:02 UTC, shares in Angiodynamics are trading at $6.26. This share price information is delayed by 15 minutes.
Shares in Angiodynamics last closed at $6.26 and the price had moved by -29.27% over the past 365 days. In terms of relative price strength the Angiodynamics share price has underperformed the S&P500 Index by -41.14% over the past year.
The overall consensus recommendation for Angiodynamics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Angiodynamics does not currently pay a dividend.
Angiodynamics does not currently pay a dividend.
Angiodynamics does not currently pay a dividend.
To buy shares in Angiodynamics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.26, shares in Angiodynamics had a market capitalisation of $250.74m.
Here are the trading details for Angiodynamics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ANGO
Based on an overall assessment of its quality, value and momentum Angiodynamics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Angiodynamics is $13.50. That is 115.65% above the last closing price of $6.26.
Analysts covering Angiodynamics currently have a consensus Earnings Per Share (EPS) forecast of -$0.52 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Angiodynamics. Over the past six months, its share price has underperformed the S&P500 Index by -21.27%.
As of the last closing price of $6.26, shares in Angiodynamics were trading -10.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Angiodynamics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Angiodynamics' management team is headed by:
- Howard Donnelly - NEC
- James Clemmer - PRE
- Stephen Trowbridge - CFO
- Richard Rosenzweig - SVP
- Chad Campbell - SVP
- Scott Centea - SVP
- Laura Piccinini - SVP
- Marna Bronfenmoore - SVP
- Benjamin Davis - SVP
- David Helsel - SVP
- Warren Nighan - SVP
- Juan Serna - OTH
- Eileen Auen - IND
- Wesley Johnson - IND
- Karen Licitra - IND
- Dennis Meteny - IND
- Jan Reed - IND
- Michael Tarnoff - IND